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In the 2012 expert consensus document on transcatheter aortic valve
replacement (TAVR), the inexact name TAVR appears in nearly every
paragraph (1). But, what’s in a name? According to William Shake-
speare, “That which we call a rose; by any other name would still
smell as sweet” (Romeo and Juliette, c. 1597). We therefore humbly
suggest reversion to the archaic name transcatheter aortic valve
implantation (TAVI). TAVR has been characterized as a disrup-
tive technology destined to change the landscape of valvular heart
disease therapy (2). A disruptive technology refers to an innovation
that ultimately displaces a proven technology already on the
market, in this case, surgical valve replacement. But how can we
accept such a bold declaration when the designation of the
procedure is a confusing misnomer?
We increasingly see poor operative candidates with severe aortic
stenosis in our multidisciplinary valve clinic. Our conversation
commences by reviewing the glossy educational pamphlet for the
Edwards Sapien Transcatheter Valve (Edwards Lifesciences LLC,
Irvine, California). The title on the front cover, above the image of
the loving elderly couple sitting on a park bench, reads “Trans-
catheter Aortic Valve Replacement.” Invariably, the first question
from an astute octogenarian is, “What happens to the old valve?”
We gracefully explain that we blow up a balloon, smash the old valve
to the side, then implant a new one within their existing annulus.
Their reaction is often one of bewilderment. This confusion is well
founded. Webster’s dictionary defines replace as “to put something
new in place of something else,” and implies filling a place once
occupied by something removed. One does not have a muffler
replaced at the local auto shop and expect to find the old one still in
place. Technically, we are performing valve displacement. However, a
valve displacement doesn’t sound like an advanced restorative therapy
that marketing experts would embrace.
With commercial release of the Sapien valve on November 2,
2011, the TAVR misnomer was memorialized: “The U.S. FDA
today approved the first artificial heart valve that can replace an
aortic heart valve damaged by senile aortic valve stenosis without
open-heart surgery” (3). Suddenly, the blogosphere described “The
Evolving TAVR Market” at NASDAQ.com, while the cardiology
community further cemented the acronym in catheterization lab-
oratories everywhere.
When did this conspicuous misuse of the English language first
occur? Results of the randomized PARTNER (Placement of
Aortic Transcatheter Valve) trial were published in a 2010 article
entitled “Transcatheter Aortic-Valve Implantation for Aortic Ste-
nosis in Patients Who Cannot Undergo Surgery” (4). TAVI was
the acronym used, and implantation seemed an appropriate de-
scription of the technology. By 2011, with publication of the
high-risk cohort of the PARTNER trial, the title somehow
transformed to “Transcatheter Versus Surgical Aortic-Valve Re-
placement in High-Risk Patients” (5).
Why does this matter? We contend that this is not merely
semantic, because an accurate name for high-risk expensive pro-
cedures is pertinent to healthcare stake holders. It facilitates
uniform communication among researchers, payers, regulators,
clinicians, and, most importantly, patients. In a clinical landscapecluttered with jargon, we should strive toward verbal precision.
Politicians, poets, and pollsters know that words matter. Powerful
words launch social movements and even cultural revolutions. The
right catch phrase also can launch a new product. However, there
should be truth in advertising, and our regulatory bodies should be
critical in determining if advertising is misleading or fails to
disclose all the relevant facts (6).
So what’s in a name? If TAVR is to alter the course of cardiovas-
cular disease care, then we believe this rose would smell sweeter with
a more accurate name. We suggest the original designation of TAVI
be the acronym of choice. This title harkens back to Rudyard Kipling’s
classic novel where the valiant mongoose, Rikki-Tikki-Tavi, con-
fronts a dreaded cobra plotting the murder of his adoptive human
family. Senile critical aortic stenosis in poor operative candidates just
may be the cardiologist’s most poisonous snake. To combat such a foe,
it is fitting that TAVI be anointed our protagonist.
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Coronary Computed Tomography
Angiography After Stress Testing
In the ACIC (Advanced Cardiovascular Imaging Consortium)
registry, Chinnaiyan et al. (1) evaluated the correlation between
stress test results and extent of coronary artery disease (CAD) on
coronary computed tomography angiography (CCTA) and com-
pared the diagnostic performance of both noninvasive modalities
in patients undergoing invasive coronary angiograms. The authors
should be commended for their attempts to answer a pertinent
debate on appropriate use of various diagnostic modalities in
